Looks at quality of life in chronic lymphocytic leukemia patients taking acalabrutinib
Reviews past records on quality of life in people with chronic lymphocytic leukemia taking acalabrutinib.
Plain-language title generated from the registry record
Registry title: AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
Key facts
- Where
- Saint-Affrique, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic lymphocytic leukemia (CLL) who are in the PLATON database and started acalabrutinib as their first treatment in routine care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Chronic lymphocytic leukemia (CLL), not treated before
- Earlier treatment
- No earlier CLL treatment. They are treated with acalabrutinib alone or with acalabrutinib plus obinutuzumab. People who stopped acalabrutinib before 12 months can also join.
Main reasons for not taking part
- Pregnant women
- People under protection of justice
- People over 18 who cannot express their non-opposition
- People who had CLL treatment before
- People who object to their PLATON health data being reused for research
Read by machine on 12 November 2026.
Where in France
- Saint-AffriqueHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06548152
- Record updated
- 27 October 2026
- Original description
QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting.Read full original descriptionShow less
AQUALIS: Quality of Life of Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France: a Retrospective Observational Study Based on Data Extracted From the PLATON Database
QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting.
The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting.
Inclusion: The following patients will be eligible for inclusion in the AQUALIS study :; -Patient enrolled in the PLATON database; -Patient ≥18 years old; -Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab; -Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose; -Patients who started Acala but discontinued before 12 months are also included; Exclusion criteria:; -Pregnant women; -Patients under protection of justice; -Patients over the age of 18 and unable to express their non-opposition; -Patients with prior CLL treatments.